In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Unity Biotechnology Inc’s stock clocked out at $1.73, up 2.37% from its previous closing price of $1.69. In other words, the price has increased by $2.37 from its previous closing price. On the day, 0.12 million shares were traded. UBX stock price reached its highest trading level at $1.75 during the session, while it also had its lowest trading level at $1.66.
Ratios:
To gain a deeper understanding of UBX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.45 and its Current Ratio is at 3.45. In the meantime, Its Debt-to-Equity ratio is 1.73 whereas as Long-Term Debt/Eq ratio is at 1.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 22, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On November 16, 2023, Wedbush Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $2 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 04 ’24 when Ghosh Anirvan sold 432 shares for $1.29 per share. The transaction valued at 557 led to the insider holds 75,893 shares of the business.
Sullivan Lynne Marie sold 136 shares of UBX for $175 on Nov 04 ’24. The CFO & Head of Corp. Dev. now owns 55,925 shares after completing the transaction at $1.29 per share. On Nov 04 ’24, another insider, Nguyen Alexander Hieu, who serves as the Chief Legal Officer of the company, sold 149 shares for $1.29 each. As a result, the insider received 192 and left with 24,723 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UBX now has a Market Capitalization of 29151192 and an Enterprise Value of 24544106.
Stock Price History:
The Beta on a monthly basis for UBX is 0.78, which has changed by 0.0058139563 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, UBX has reached a high of $2.02, while it has fallen to a 52-week low of $0.94. The 50-Day Moving Average of the stock is 39.52%, while the 200-Day Moving Average is calculated to be 22.03%.
Shares Statistics:
It appears that UBX traded 148.57K shares on average per day over the past three months and 477370 shares per day over the past ten days. A total of 16.85M shares are outstanding, with a floating share count of 15.37M. Insiders hold about 8.80% of the company’s shares, while institutions hold 13.14% stake in the company. Shares short for UBX as of 1735603200 were 244020 with a Short Ratio of 1.64, compared to 1732838400 on 258375. Therefore, it implies a Short% of Shares Outstanding of 244020 and a Short% of Float of 1.46.
